Abstract:BackgroundBeta blockers form one of the mainstay therapies for myocardial infarction (MI). Preclinical studies have shown efficacy and safety of thyroid hormone (TH) treatment of cardiovascular disorders. Although THs interact with the sympathoadrenal system at various levels, crosstalk between TH signaling and β‐adrenergic signaling remains poorly understood. We compared pathophysiologic and TH‐adrenergic signaling changes between therapeutic doses of triiodothyronine (T3) and metoprolol (Met) in rats with MI.MethodsFemale Sprague‐Dawley rats aged 12 weeks underwent left anterior descending coronary artery ligation (MI) or sham surgeries. T3 (5 μg/kg/d) or Met (100 mg/kg/d) were given in drinking water immediately after surgery for 8 weeks. At terminal experiments, rats were subjected to morphological, functional, and molecular examination.ResultsT3 and Met significantly enhanced left ventricular (LV) fractional shortening (LVFS 21.4±2.6% and 21.1±3.7%, respectively) compared to untreated MI (17.9±1.2%) and decreased the incidence of inducible atrial tachyarrhythmia by 87.5% and 62.5% without producing untoward effects. Although both treatments showed efficacy, T3 but not Met showed statistically significant improvements compared to MI in arrhythmia duration, left atrial diameter (T3 vs MI 4.3±0.6 vs. 5.7±1.3 mm, p<0.05; Met 4.9±1.1), fibrosis (6.1±0.6%, 6.6±0.6% vs. 8.2±0.7%, T3, Met vs. MI, respectively) and aortic vasorelaxation responsiveness (pD2 6.97±0.22, 6.83±0.21 vs. 6.66±0.22, T3, Met vs MI, respectively). Quantitative PCR showed that T3 and Met attenuated expression of genes associated with inflammation and oxidative stress and restored expression of ion channels and contractile proteins compared to MI rats. Importantly, thyroid and β‐adrenergic signaling genes were favorably regulated by both treatments.ConclusionThese results support comparable efficacy of long‐term treatment with a physiological dose of T3 that is comparable to Met and suggest a potential therapeutic alternative to standard β‐blockade for patients intolerant to treatment with β‐blockers after MI.Support or Funding InformationThis work was supported by the National Heart, Lung, and Blood Institute of the NIH, Bethesda, MD, under Award Number R01HL103671 (AG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledged the National Natural Science Foundation of China (No. 81470485), Capital Clinical Featured Application Research Project (NO. z151100004015175) and CAMS Innovation Fund for Medical Sciences (CIFMS 2016‐I2M‐1‐009).This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats.

Comparative Transcriptome Analysis Reveals the Potential Cardiovascular Protective Targets of the Thyroid Hormone Metabolite 3-Iodothyronamine (3-T1AM).

Adverse Transverse-Tubule Remodeling in a Rat Model of Heart Failure is Attenuated with Low-Dose Triiodothyronine Treatment.

Abstract P247: Triiodothyronine Ameliorates Endothelial Dysfunction in Rats Following Acute Myocardial Infarction

Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats

Crosstalk Between Thyroid Hormone Signaling and Β‐adrenergic Signaling in Myocardial Infarction

The Effects of Therapeutic Hypothermia on the Expression of DKK3 and Myocardial Ischemia-Reperfusion Injury

3-iodothyronamine inhibits apoptosis induced by myocardial ischemia reperfusion via the Akt/FoxO1 signaling pathway

Effects of triildothyronine on the functions of Na+-K+ pump and Ca2+ pump in myocytes

Thyroid Hormone Metabolite 3-Iodothyronamine (T1AM) Alleviates Hypoxia/Reoxygenation-Induced Cardiac Myocyte Apoptosis via Akt/FoxO1 Pathway

Triiodothyronine Maintains Cardiac Transverse-Tubule Structure and Function.

Short-Term Pretreatment with Atorvastatin Attenuates Left Ventricular Dysfunction, Reduces Infarct Size and Apoptosis in Acute Myocardial Infarction Rats

L-Tetrahydropalmatine, An Active Component Of Corydalis Yanhusuo W.T. Wang, Protects Against Myocardial Ischaemia-Reperfusion Injury In Rats

Propranolol inhibits myocardial infarction-induced brown adipose tissue D2 activation and maintains a low thyroid hormone state in rats

Tanshinone IIA Protects Against Sudden Cardiac Death Induced by Lethal Arrhythmias Via Repression of Microrna‐1

The Pharmaeological Preconditioning of Triiodothyronine on Myocardial Protection

Thyroid hormone improves the mechanical performance of the post-infarcted diabetic myocardium: a response associated with up-regulation of Akt/mTOR and AMPK activation

Thyroid Hormone Replacement in Heart Failure Combined with Nonthyroid Illness Syndrome

Translating thyroid hormone into clinical practice: lessons learned from the post-hoc analysis on data available from the ThyRepair study

Tanshinone‑IIA Inhibits Myocardial Infarct Via Decreasing of the Mitochondrial Apoptotic Signaling Pathway in Myocardiocytes.

Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy.